Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Researchers need your help. By taking part in research studies and clinical trials, you will help them make progress to improve lives and find a cure for type 1 diabetes.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Your donation helps support people living with type 1 diabetes and funds the best treatment and cure research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & events > News > Partnership funding autoimmune research now has over 10 members
Myaware, the only charity in the UK focusing on people affected by myasthenia, is the latest organisation to join Connect Immune Research. Growing the pool of experts dedicated to finding a root cause of auto immune conditions accelerates us towards innovative new ways of treating autoimmunity.
Connect Immune Research is a revolutionary partnership of organisations that research autoimmune conditions, where the body’s immune system attacks its own cells rather than viruses and bacteria. The initiative pools resources from the member organisations to fund vital research into the overlapping biology of autoimmune conditions. The more organisations we have working together, the closer we’ll be to achieving our common goal of understanding and treating the causes of autoimmunity.
JDRF UK, Versus Arthritis, the MS Society and the British Society for Immunology founded Connect Immune Research with the mission to find shared causes of autoimmune conditions. Having recruited seven new members, the partnership now stands at 11 autoimmune research organisations, demonstrating the value the research community sees in working beyond individual conditions to tackle autoimmunity.
Dr David Coutts, Senior Research Manager at the MS Society, said: “We’re delighted to welcome myaware to our Connect Immune Research partnership. Around four million people in the UK have an autoimmune condition like multiple sclerosis, rheumatoid arthritis or type 1 diabetes, and up to a third of people live with more than one of these conditions at once. Research into autoimmune conditions often only looks at a single condition, like MS, or a single organ, like the brain. We believe by linking up research and looking for common threads, we’ll be better able to treat these conditions in the future.
“As well as speeding up research into new treatments for millions of people with autoimmune conditions, the approach could also dramatically reduce costs. We want autoimmunity to be recognised as a distinct area of research science, alongside the likes of cancer, infectious disease and dementia.”
Myasthenia is a group of conditions, most of which are autoimmune, causing weakness in the body’s voluntary muscles and the muscles that control breathing.
Myaware, whose tagline fighting myasthenia together aligns closely with the values of Connect Immune Research, are the latest charity to join the partnership.
The wide range of organisations now united to tackle autoimmunity expands our portfolio of expertise and boosts our research prospects. Ultimately, this will help us gain crucial insights about autoimmunity that could lead to new treatments for people living with autoimmune conditions.
We are delighted with the decision to approve teplizumab for use on the NHS.
We look at a new feature coming to the CamAPS FX app, which will allow users to remove the need to count carbohydrates before a meal.
In draft guidance published today, NICE recommends that anyone with type 1 diabetes who is pregnant or planning a pregnancy should be offered pregnancy-specific HCL technology.
Discussing the main themes from this year's Advanced Technologies & Treatments for Diabetes conference – early detection, cellular cures and disease-modifying therapies.
Don’t miss out on the latest research, inspiring stories, tech news, upcoming events, and handy information on living well with type 1. Join us now and receive it all straight to your inbox.
It’s thanks to your dedication that we have funded great progress in type 1 cure, treatment and prevention research. Help us to continue our vital research.
Would you like to visit the website of our {{ affiliate_country }} affiliate to complete your action?
